Treatment of moderate‐to‐severe canine atopic dermatitis with modified‐release mycophenolate ( OKV ‐1001): A pilot open‐label, single‐arm multicentric clinical trial
Veterinary Dermatology · 2024
DOI: 10.1111/vde.13283 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Veterinary Dermatology, 2024. Verfasst von Michael Klotsman und 5 weiteren Autor:innen. Beteiligte Einrichtung: Okava Pharmaceuticals, San Francisco, California, USA. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Dog Diseases, Mycophenolic Acid, Drug Liberation. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Okava Pharmaceuticals.
Abstract (Originalsprache)
Background
Mycophenolate is an immunomodulating agent successfully used for the treatment of moderate‐to‐severe atopic dermatitis (AD) in people. Mycophenolate is an effective steroid‐sparing treatment option for use in dogs with inflammatory skin diseases.
Objective
To evaluate whether once‐daily modified‐release mycophenolate (OKV‐1001) is safe and effective for treating moderate‐to‐severe canine AD. Animals Client‐owned atopic dogs ( n = 9) were enrolled. Materials and Methods In an open‐label multicentre pilot study, OKV‐1001 (30 mg/kg every 24 h) was given orally for ≤84 days. Concomitant tapering doses of glucocorticoids were administered up to Day (D)28. Clinicians assessed Canine Atopic Dermatitis Extent and Severity Index, 4th iteration (CADESI‐04) on D0, D14, D28, D56 and D84. Body weight and clinical pathological parameters were measured at baseline and at the end of the study.
Results
Treatment with OKV‐1001 combined with glucocorticoids significantly reduced the severity of AD within two weeks in seven of nine (77.8%) dogs. The mean percentage change from baseline in the CADESI‐04 score was 29% ( p = 0.009) at D14 ( n = 9), 39% ( p = 0.008) at D28 ( n = 9) and 49% ( p = 0.03) at D56 ( n = 7) at which point glucocorticoids had been withdrawn. In two dogs the improvement in CADESI‐04 was 62% and 23% (respectively) on D84. No significant adverse events including clinical pathological findings were reported. Conclusions and Clinical Relevance Modified‐release mycophenolate (OKV‐1001) may represent a promising alternative treatment option for dogs with moderate‐to‐severe AD. The safety and efficacy profile of OKV‐1001 will need to be established in larger, placebo‐controlled clinical trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Okava Pharmaceuticals, San Francisco, California, USA.
- Pulmonary and Critical Care Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
- Dermatology Clinic for Animals, Lacey, Washington, USA.
- Dermatology for Animals, Gilbert, Arizona, USA.
- MedVet Columbus, Worthington, Ohio, USA.
- Department of Small Animal Clinical Sciences, College of Veterinary Medicine, University of Florida, Gainesville, Florida, USA.
ORCID-Profile: Domenico Santoro
Förderung
- Okava Pharmaceuticals
Zitieren
APA
Klotsman, M., Anderson, W. H., Wyatt, D., Lewis, T., Theus, N., & Santoro, D. (2024). Treatment of moderate‐to‐severe canine atopic dermatitis with modified‐release mycophenolate ( OKV ‐1001): A pilot open‐label, single‐arm multicentric clinical trial. Veterinary Dermatology. https://doi.org/10.1111/vde.13283
Vancouver
Klotsman M, Anderson WH, Wyatt D, Lewis T, Theus N, Santoro D. Treatment of moderate‐to‐severe canine atopic dermatitis with modified‐release mycophenolate ( OKV ‐1001): A pilot open‐label, single‐arm multicentric clinical trial. Veterinary Dermatology. 2024. doi:10.1111/vde.13283
BibTeX
@article{Klotsman2024,
author = {Klotsman, Michael and Anderson, Wayne H and Wyatt, Danielle and Lewis, Tom and Theus, Natalie and Santoro, Domenico},
title = {Treatment of moderate‐to‐severe canine atopic dermatitis with modified‐release mycophenolate ( OKV ‐1001): A pilot open‐label, single‐arm multicentric clinical trial},
journal = {Veterinary Dermatology},
year = {2024},
doi = {10.1111/vde.13283}
}
EUVIMED